Taj Singh

Macquarie Capital Markets

Recent Articles

Delay in New Drug Filing Now Could Yield Benefits Later 08/29/2022

The developer of genetic medicines is taking six more months to conduct longer preclinical safety studies involving its lead therapeutic, noted an Oppenheimer report.

First Data Due by Year End 2022 From Study of New HAE Drug 08/24/2022

Management's ongoing execution is raising the biopharma's profile among investors, noted an Oppenheimer report.

Recent Quotes

"We maintain our Outperform rating for TMM."

— Taj Singh, Macquarie Capital Markets (8/14/12)
more >

"TMM possesses strong exploration upside and an attractive valuation."

— Taj Singh, (4/11/12)
more >

Due to permission requirements, not all quotes are shown.